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Background: The immunopathogenesis of pediatric multiple sclerosis (MS) is not well understood.
Methods: We studied the cytokine profile in pre-treatment serum specimens of 19 pediatric MS patients, 25 adult
MS patients, and 22 age- and gender-matched pediatric healthy controls. In addition to IL-2, IL-12p40, IL-12p70, IL-18,
IL-23, IL-6, TNF-α, TGF-β-1, IFN-γ, IL-17A, IL-21, IL-10, IL-4, IL-5, IL-13, and GM-CSF, we measured osteopontin and soluble
VCAM-I.
Results: In children with MS, significantly lower levels of IL-6 were present compared to age- and gender-matched
healthy control children (p < 0.05). Moreover, significantly higher levels of osteopontin (p < 0.02) and sVCAM-1 (p < 0.02)
and lower levels of IL-6 (p < 0.01) were present, with trends toward lower levels of IL-12p70 (p = 0.074) and IL-17a (p =
0.05) compared to adults with MS.
Conclusions: These findings indicate important differences in cytokine signatures in children with MS and suggest an
unexpected possible lower inflammatory cytokine profile in children with MS.
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The pathophysiology of multiple sclerosis (MS) is or-
chestrated by an array of molecular messengers known
as cytokines. These signaling molecules are produced by
or modulate the activity of T-cells and other immune
cells. Many studies in adult MS have examined individ-
ual cytokines or their profiles to better characterize the
pathogenesis of this disease, but only a limited number
of studies have examined pediatric patients with MS.
Studies in experimental autoimmune encephalomyeli-
tis (EAE), the animal model of MS, and in adult MS pa-
tients have identified disease-associated cytokines that
are thus characterized as pro-inflammatory and con-
versely anti-inflammatory for those associated with dis-
ease remission or amelioration. In serum and CSF
studies of adult MS patients, elevations of pro-
inflammatory IL-2, IL-12, IL-6, TNF-α, and IFN-γ, as
well as anti-inflammatory/regulatory IL-10, IL-4, and* Correspondence: bhisevi@rwjms.rutgers.edu
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Martins et al of 833 adult subjects with MS and 117
healthy controls using a protocol similar to our study
found elevations in pro-inflammatory IFN-γ, IL-2, IL-1B,
and TNF-α, and anti-inflammatory IL-4, IL-10, and IL-
13 [2]. Higher levels of IL-18, IL-23, and IL-17 are also
seen in the serum of MS patients compared to healthy
controls [3].
Pediatric MS has distinct features from adult MS in-
sinuating important differences are to be found in the
immune profile. The vast majority of patients (over
95 %) present with a relapsing-remitting course. Com-
pared to adults with MS, pediatric-onset individuals have
higher relapse rates and shorter times to their second at-
tack, but better recovery from relapses [4, 5]. CSF stud-
ies in younger children possess more inflammatory
features with greater neutrophilic counts than older chil-
dren, and are less likely to demonstrate oligoclonal
banding [6]. Additionally, for these younger patients,
MRI lesions may resolve entirely over the course of a
few months [7]. Disability milestones take on average
5 years longer to reach in children compared to adultsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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inflammatory pathophysiology in childhood MS.
Published studies in pediatric MS pathophysiology
have focused on humoral and cellular aspects of the
disease. Children with central demyelinating disease
demonstrate increased peripheral T-cell proliferation
responses to myelin-based and dietary antigens when
compared to healthy controls [9]. Additionally, there
may be elevated myelin oligodendrocyte glycoprotein
(MOG) antibodies, particularly in patients under 10 years
of age [10, 11], and higher affinity antibodies present for
myelin-basic protein in children [12]. A recent study iden-
tified elevated CSF complement anaphylatoxins C5a, C4a,
and C3a, and CSF IL-6 levels in children with either
monophasic central demyelination or MS, higher in the
former, when compared to other neurological diseases
[13]. In addition, plasma MOG antibodies in monophasic
disease and MS both correlated with CSF IL-6 levels.
These differences confirm evidence of abnormal immune
physiology in children with demyelinating disease, but lack
comparison to adult cohorts.
Our specific aims in this study were to establish a
baseline cytokine profile in pediatric MS patients and to
compare this profile to that in age- and gender-matched
healthy controls and adults with MS to identify cytokine
signatures unique to pediatric-onset MS.
Methods
MS patients were enrolled in the study at the time of an
outpatient clinic visit to the MS Comprehensive Care
Center at RWJMS, the Child Health Institute of NJ, and
the Pediatric MS Center at Stony Brook, NY and met
2010 McDonald [14] and/or International Pediatric MS
Study Group (IPMSSG) consensus criteria for MS [15].
Peripheral pre-treatment serum samples were collected
from 19 pediatric MS patients, 25 adult MS patients,
and 22 age- and gender-matched pediatric healthy con-
trols, centrifuged at 1500 rpm for 15-20 minutes and
then stored as serum in a -70 ° C freezer. Cytokine ana-
lysis was performed using the Cytometric Bead Array im-
munoassay at a commercial laboratory center (Millipore).
The MILLIPLEX™ MAP technology uses microspheres
color coded with two fluorescent dyes each and coated
with specific antibodies. Following capture, an analyte is
bound by a biotinylated detection antibody and then
incubated with a Streptavidin-Phycoerythrin conjugate,
completing the reaction. The microspheres then pass
through two lasers, the first exciting the internal dye, the
second, the conjugate dye. High-speed digital processors
quantify the fluorescent signals. Multiple microspheres
may be used to detect multiple analytes in a single ultra
low volume sample.
The following cytokines were tested: IL-2, IL-12p40, IL-
12p70, IL-18, IL-23, IL-6, TNF-α, IFN-γ, IL-17A, IL-21,and osteopontin as measures of pro-inflammatory activity,
and IL-10, IL-4, IL-5, IL-13, GM-CSF, sVCAM-I, and
TGF-β-1as measures of anti-inflammatory activity.
All enrolled pediatric MS patients were post-pubertal.
Clinical data for pediatric MS subjects collected included
most recent prior brain MRI lesion count, contrast-
enhancing lesion number, T1 hypointense black hole
number, time from first event, time from last event, total
number of prior attacks, time to next clinical attack,
CSF oligoclonal bands, CSF IgG index, CSF white blood
cell (WBC) count, and nearest serum vitamin D level.
Patients did not receive IV steroids within the 30 days
prior to the specimen collection and were naïve to
disease-modifying therapy. Adult MS patients had fewer
overall relapses and longer disease durations on average.
Statistical analysis was performed using SigmaPlot.
Results classified as below laboratory detection standards
were scored as 0. Data was analyzed for normality test-
ing followed by application of the Mann-Whitney rank
sum test, except for unpaired two-tailed T-test on
sVCAM data which was normally distributed with equal
variances. Statistical significance was determined by
p-value <0.05. Fisher's exact test and student T-test
were used to compare patient demographic data. Post
hoc-analyses were conducted for vitamin D level,
number of attacks, CSF WBC count, time from last
clinical attack to blood draw, time from first clinical
attack to blood draw (i.e. disease duration), baseline
MRI T2 lesion number, and presence of gadolinium-
enhancing lesions on baseline MRI.
Results
Mean age and gender distribution were not significantly
different between healthy controls and pediatric MS pa-
tients (see Table 1), nor gender distribution between
adult and pediatric MS. Differences in several cytokines
were identified.
Comparison to healthy controls
Lower levels of IL-6 were seen in patients with pediatric
MS compared to pediatric healthy controls (p = 0.046)
(see Table 2). Patients with pediatric MS also had lower
levels of GM-CSF, IFN-γ, IL-12p70, and IL-17A com-
pared to healthy controls, but these differences were not
identified as significantly different. A non-significant ele-
vation in IL-23 was also observed in pediatric MS pa-
tients compared to pediatric healthy controls (p = 0.11).
Comparison to adult MS
Levels of interferon (IFN)-gamma were lower in
pediatric MS patients compared to both adult MS patients
and healthy pediatric controls, though not significant.
IL-12p70 was also lower in pediatric MS patients com-
pared to adults with MS but not significant (p = 0.074).
Table 1 Demographics
Untreated Pediatric MS Untreated Adult MS Pediatric Healthy Controls
Female 12 (63 %)* 19 (76 %)*** 16 (73 %)
Male 7 (37 %) 6 (24 %) 6 (27 %)
Age mean (SD) 16.0 years (1.4)** 37.9 years (10.5) 15.6 years (1.7)
Age range (y) 13.4-18.0 19.0-54.7 12.3-17.9
No. attacks mean 2.1 1.4****
Disease duration mean (months) 6.9 54.5
* p = 0.74 HC vs PMS, ** p = 0.33 HC vs PMS, *** p = 0.51 HC vs AMS, **** p =0.08 PMS vs AMS (in past 2 years)
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to adults with MS (p = 0.050 and p = 0.004 respectively).
Adult MS patients had lower sVCAM-1 levels than
patients with pediatric MS (p = 0.015). However, no differ-
ence in sVCAM-1 was noted between pediatric healthy
controls and patients with pediatric MS.
Clinical correlation
No significant correlations were present for patients with
vs without contrast-enhancing brain MRI lesions, num-
ber of clinical attacks prior to sample collection, total
CSF WBCs, or MRI total brain lesion count with serum
levels of cytokines. Testing for CSF oligoclonal bands
was positive in all but one patient but the number of
unique bands was listed for only a few. CSF IgG index
on the other hand was only available for 6 patients.
Serum levels of TGF-β-1 negatively correlated (-0.69)
with serum vitamin D levels (p < 0.01). Serum IL-17F
levels had a modest positive correlation (0.47) with time
from first clinical attack (p < 0.05).
Discussion
Serum levels of IL-6 were significantly lower in children
with MS compared to healthy controls (p = 0.046) and
adults with MS (p = 0.004). In contrast, serum IL-6 ap-
pears to correlate positively with disease activity in other
inflammatory childhood diseases such as Kawasaki dis-
ease, juvenile inflammatory arthritis (JIA), and ulcerative
colitis [16–18]. Indeed, anti-IL-6 therapy is currently in
use for JIA [19]. IL-6 is a multifunctional cytokine pro-
duced by many cell types in response to infection, butTable 2 Select mean serum cytokine values
IL-6 sVCAM-1 Osteo
Peds MS (n = 19) 2.1 (8) 479,253 (120,408) 16,506
Adult MS (n = 24) 12.5 (22) 408,110 (118,417) 10,557
Pediatric Healthy Controls (n = 22) 18.2 (31) 497,982 (128,890) 14,240
(10,71
HC vs Peds MS (p) 0.046 0.637 0.255
Adult MS vs Peds MS (p) 0.004 0.015 0.022
* Mean value of cytokine concentration in serum in pg/ml
** Standard deviation values are listed in parentheses ()
Significant findings listed in boldalso plays a pro-inflammatory role in incurring EAE
[20–22]. These actions are mediated by the soluble form
of the IL-6 receptor (IL-6R) that may be induced by up-
regulation of ICAM-1 and VCAM-1, which allows TH1
cell entry into the CNS. Previous studies have shown el-
evated IL-6 levels in the CSF of patients with ADEM
which correlates with the presence of anti-MOG anti-
bodies. [13, 23, 24] In MS lesions, T-cells, microglia, and
activated astrocytes secrete IL-6 in the setting of aug-
mented receptor responses [25]. This cytokine also ap-
pears to stimulate TH17 differentiation and inhibits
TGF-β Treg cell formation [25]. IL-6 also maintains a
separate anti-inflammatory and neuroprotective function
through oligodendrocyte differentiation, neurotropism,
and peripheral nerve regeneration mediated by the
membrane-bound IL-6R on select cells such as microglia
[26]. Human monocytes are directed away from differen-
tiation into dendritic cells and toward macrophages
which have increased anti-inflammatory IL-4 and IL-10
and decreased IL-1β production [27]. Given the dual
roles of IL-6, it is possible the relative balance between
the two pathways shifts with age. Further studies could
examine prepubertal patients with MS to search for even
starker differences.
Cytokine levels for IL-6 were found to be significantly
lower in patients with pediatric MS than adults with MS, as
were IFN-γ, IL-12p70, and IL-17A (though not statistically
significant), while osteopontin and sVCAM were higher.
These findings are somewhat surprising, as all the markers
save for osteopontin and sVCAM that were identified
as significantly different indicate a greater inflammatorypontin IL-17A GM-CSF IFN-γ IL-12p70 IL-23
(8913) 19.3 (28) 10.2 (40) 41.6 (64) 11.9 (28) 1599 (4809)
(5336) 40.9 (44) 7.3 (19) 72.1 (91) 33.3 (57) 490 (1307)
*
8)**
41.0 (54) 40.1 (109) 74.6 (91) 39.6 (86) 820 (1499)
0.454 0.302 0.408 0.112 0.108
0.050 0.742 0.248 0.074 0.334
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clinical nature of patients with pediatric MS, it was antici-
pated that that all these markers would be elevated instead
relative to adults with MS. This may represent a substantial
finding which challenges the little-known pathophysiology
in early-onset MS. These results highlight that these par-
ticular cytokines may be useful markers of disease activity.
Alternatively, given the small sample size, these findings
may be driven by chance (Type 1 error), for example by in-
advertent selection of patients with relatively low disease
activity.
Soluble vascular cell adhesion molecule-I (sVCAM-I) is
elevated in MS patients and correlates with clinical and
MRI disease activity [28–30]. Five samples were found to
be erroneously collected from post-treatment patients, 3
with Rebif and 2 with Copaxone all started a few months
prior to sample collection. These patients were not in-
cluded (original n = 24) in the statistical analysis. The sam-
ple size of 5 patients may be too low to support meaningful
findings, but we did note elevated mean levels of osteopon-
tin and sVCAM-1 in the treated patients compared to un-
treated patients (as well as controls), which was significant
for sVCAM-1 (p = 0.011). In line with prior studies,
interferon-β increases sVCAM levels [31–33], but rather is
noted to downregulate osteopontin [34]. It is unclear if
osteopontin represents a variant pathway in pediatric MS.
The negative correlation identified between serum levels
of TGF-β-1 and serum vitamin D levels (p < 0.01) high-
lights other studies in MS and findings that vitamin D
supplementation may increase TGF-β expression, which
may play a role in its mechanism of action [35–37].
TGF-β-1 is an anti-inflammatory cytokine produced by
regulatory T-cells. In mouse models of EAE, vitamin D
administration induces TGF-β-1 production, [38], while
exogenous TGF-β-1 ameliorates the disease [39]. Human
derived T-cell lines from active MS patients produce less
TGF-β-1 than stable patients [40]. Other studies indicate
effects on TGF-β-2 instead [41]. In our pretreatment co-
hort, we may be seeing compensatory efforts to elevate
TGF-β where vitamin D is lacking.
The correlation between serum IL-17 F levels and time
from first clinical attack (p < 0.05) may explain the lack
of certain significant findings in cytokine profiles if time
from clinical attack is relevant. Thus, acquiring samples
at the time of relapse may be informative as well and a
useful goal for future studies. Lower levels of IL-17 at
the time of attack and lower levels of IL-6 in children
compared to adults may implicate pediatric MS as a
more TH1 mediated disease. Possibly TH17 activity be-
comes a more prominent feature with disease chronicity
or is simply not well developed in early MS. Neverthe-
less, IL-17 responses do appear to play a role, but may
explain why concomitant responses in IL-6 and TGF-β
are not seen [42].Osteopontin is classified as a TH1 cytokine, as it has di-
verse effects on inflammation, cell survival, cell-mediated
immunity, bone mineralization, and more [43, 44]. Vari-
ous cells produce this cytokine which induces IL-12 and
IFN-γ and inhibits IL-10 expression from monocytes.
OPN-deficient EAE mice show milder disease [45]. Ele-
vated levels are seen in CSF and plasma of MS patients,
even greater at times of relapses [46, 47].
Conclusions
A panel of inflammatory markers, namely IL-6, sVCAM-
1, osteopontin, and IL-17A, have been found differen-
tially expressed in serum samples of children with MS
compared to pediatric healthy controls and adults with
MS. The combination of findings suggests a lower in-
flammatory profile in children with MS compared to
adult MS, contrary to clinical expectations. Future pro-
spective studies with larger samples sizes and cohorts in-
cluding prepubertal patients are needed to validate this
pilot data and assess if they are prognostic of disease
outcome. The absence of longitudinal samples in this
study limits further interpretation. Such studies would
also benefit from serial samples including post-treatment
assessment. Additional investigations should also focus
on cell types that express or are targeted by the cyto-
kines identified in this study as well as broader examin-
ation of CSF.
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